550 related articles for article (PubMed ID: 3053124)
21. Drugs for treatment of peptic ulcers.
Dajani EZ; Trotman BW
J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999
[TBL] [Abstract][Full Text] [Related]
22. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
Bianchi Porro G; Parente F
J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
[TBL] [Abstract][Full Text] [Related]
23. Medical treatment of peptic ulcers.
Deveney CW; Deveney KE
Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer.
Vantrappen G; Schuurmans P; Rutgeerts P; Janssens J
Scand J Gastroenterol Suppl; 1982; 80():23-30. PubMed ID: 6761849
[TBL] [Abstract][Full Text] [Related]
25. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
[TBL] [Abstract][Full Text] [Related]
26. The actions of bismuth in the treatment of Helicobacter pylori infection.
Lambert JR; Midolo P
Aliment Pharmacol Ther; 1997 Apr; 11 Suppl 1():27-33. PubMed ID: 9146788
[TBL] [Abstract][Full Text] [Related]
27. Drug therapy for peptic ulcer: drugs that act on the gastric mucosa.
Kauffman GL
J Clin Gastroenterol; 1981; 3(Suppl 2):95-101. PubMed ID: 6119340
[TBL] [Abstract][Full Text] [Related]
28. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.
Miller JP; Hollanders D; Ravenscroft MM; Tweedle DE; Martin DF
Scand J Gastroenterol Suppl; 1982; 80():39-42. PubMed ID: 6761851
[TBL] [Abstract][Full Text] [Related]
29. Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse.
Bardhan KD; Singh S; Morris P; Thompson M; Hinchliffe RF; Cary BA; Wall RM; Blakemore CB
Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):128-34. PubMed ID: 9646192
[TBL] [Abstract][Full Text] [Related]
30. Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.
Eberhardt R; Kasper G
Rev Infect Dis; 1990; 12 Suppl 1():S115-9. PubMed ID: 2406852
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats.
Konturek SJ; Dembinski A; Warzecha Z; Bielanski W; Brzozowski T; Drozdowicz D
Gut; 1988 Jul; 29(7):894-902. PubMed ID: 3260885
[TBL] [Abstract][Full Text] [Related]
32. The role of colloidal bismuth subcitrate in gastric ulcer and gastritis.
Tytgat GN; Rauws E; Langenberg W
Scand J Gastroenterol Suppl; 1986; 122():22-9. PubMed ID: 3535018
[TBL] [Abstract][Full Text] [Related]
33. A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcers.
Ward M; Halliday C; Cowen AE
Digestion; 1986; 34(3):173-7. PubMed ID: 3530861
[TBL] [Abstract][Full Text] [Related]
34. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold SP; Campoli-Richards DM
Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
[TBL] [Abstract][Full Text] [Related]
35. Colloidal bismuth subcitrate (De-Nol) inhibits degradation of gastric mucus by Campylobacter pylori protease.
Sarosiek J; Bilski J; Murty VL; Slomiany A; Slomiany BL
Am J Gastroenterol; 1989 May; 84(5):506-10. PubMed ID: 2470250
[TBL] [Abstract][Full Text] [Related]
36. Newer drugs in the treatment of peptic ulcer.
Tandon BN
Trop Gastroenterol; 1985; 6(4):188-92. PubMed ID: 3913076
[No Abstract] [Full Text] [Related]
37. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
38. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
[TBL] [Abstract][Full Text] [Related]
39. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Langtry HD; Wilde MI
Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
[TBL] [Abstract][Full Text] [Related]
40. Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing.
McLean AJ; Harcourt DM; McCarthy PG; Dudley FJ; McNeil JJ
Med J Aust; 1987 Apr; 146(8):431-3, 436-8, 442. PubMed ID: 2886896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
